|Articles|April 1, 2003

Oral Pimecrolimus

Maui, Hawaii - A 12-week dose-finding study evaluating oral pimecrolimus for the treatment of chronic plaque-type psoriasis has yielded encouraging safety and efficacy results, Alice B. Gottlieb, M.D., Ph.D., said at the annual Hawaii Dermatology Seminar, sponsored by the Skin Disease Education Foundation.

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.


Latest CME